3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Recruiting
1
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
22
Gastrointestinal
14
Breast
13
Thoracic
12
Head & Neck
10
Gynecologic
10
Dermatologic
9
Sarcoma
5
CNS
3
Plasma cell
1
Other neoplasm
1
NET
1
Myeloid
1
Endocrine
1
Classical hematology
1
Conditions
Leukemia, Myeloid, Acute
38
Anemia, Refractory, with Excess of Blasts
31
Venous Thromboembolism
24
Myelodysplastic Syndromes
21
Neoplasms
16
Precursor Cell Lymphoblastic Leukemia-Lymphoma
15
Leukemia
14
Anemia, Aplastic
14
Thrombocytopenia
10
Lymphoma, Non-Hodgkin
10
Lymphoma
10
Leukemia, Myelomonocytic, Chronic
10
Myeloproliferative Disorders
9
Anemia
9
Venous Thrombosis
8
Primary Myelofibrosis
8
Multiple Myeloma
8
Hodgkin Disease
8
Hematologic Neoplasms
8
Cytopenia
8
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
7
Febrile Neutropenia
7
Congenital Bone Marrow Failure Syndromes
7
Anemia, Sickle Cell
7
Pulmonary Embolism
6
Leukemia, Lymphocytic, Chronic, B-Cell
6
Leukemia, Biphenotypic, Acute
6
Fanconi Anemia
6
Bone Marrow Failure Disorders
6
Immunologic Deficiency Syndromes
5
Interventions
Rivaroxaban
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Urogenital Neoplasms
×
Classical hematology
×
Clear all
NCT05920343
2025-07-10
PREVENT-GU
Ottawa Hospital Research Institute
Phase 2/3
Recruiting
120 enrolled